Which Country Is Opdivo (Nivolumab) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Opdivo (nivolumab) is, like Keytruda, a PD-1 immune checkpoint inhibitor given by hospital infusion, so it is procured through institutional channels rather than sold across a pharmacy counter. Türkiye's baseline mechanism sets the reference price from the lowest ex-factory price across a designated basket of five to ten EU member states, then converts using the "pharmaceutical euro" (Dönemsel Avro Değeri), fixed at 65% of the prior year's average Central Bank euro rate rather than the current spot rate — a rule published through the TİTCK price list and the Resmî Gazete. That structural gap between a fixed reference rate and the market exchange rate is a large part of why Opdivo's published Turkish price sits below markets with free pricing.

In Germany, oncology biologics like Opdivo enter the market under AMNOG at a free launch price for the first six months, after which a negotiated price applies retroactively from month seven onward. The UK's NICE evaluates such drugs against a cost-per-QALY threshold that rose from £20,000–£30,000 to £25,000–£35,000, announced 1 December 2025 and effective April 2026 (NICE). Neither mechanism sets a number you can compare directly to a Turkish, US, or Gulf list price — they are different regulatory processes producing different published figures.

The United States sets no equivalent reference price at all: pricing for a checkpoint inhibitor like Opdivo is effectively free at launch and negotiated privately between the manufacturer, insurers and pharmacy benefit managers. The RAND international price comparison (2022 data, published 1 February 2024) found US gross list prices at 278% of prices across 33 other high-income countries for all drugs and 422% for brand-name originators — a structural pattern that applies across the checkpoint-inhibitor class generally, not a claim about Opdivo specifically.

Because Opdivo is hospital-administered, list price and actual acquisition cost diverge further once tenders and confidential discounts are factored in. A Frontiers in Pharmacology study published 9 March 2026, covering 23 hospitals across 9 European countries, found actual hospital prices running 7%–38% below published reference prices for the same category of products. Read any country comparison, including this one, as a comparison of list prices only. For the underlying pricing logic behind Türkiye's published figures, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Opdivo I'm being offered genuine?

No WHO Medical Product Alert for falsified Opdivo appears in our catalogue at the time of writing. That absence is worth stating plainly rather than glossing over — but it is not evidence that falsified Opdivo does not exist, only that it has not surfaced in the alerts we track. WHO alert coverage depends on national regulators reporting incidents, and gaps in the record are common for products sold through less-monitored channels.

Because there is no drug-specific alert to check against, the physical and documentary checks below matter more, not less: they are the only verification available in the absence of a public alert history for this specific product.

• Scan the carton's GS1 DataMatrix and confirm it decodes correctly to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch); treat any mismatch as disqualifying.
• For Turkish-sourced stock, verify the karekod is registered on the national İlaç Takip Sistemi (İTS) track-and-trace platform at its.saglik.gov.tr.
• Request a continuous 2–8°C temperature record for the specific shipment, since Opdivo must never be frozen or shaken and a generic certificate proves nothing about your batch.
• Even without an Opdivo-specific alert, check the current list at our WHO falsified medicine alerts tracker in case a new report has been added.
• Be wary of any site offering a public "manufacturer batch checker" — no major oncology manufacturer runs one, so a site claiming to is a red flag rather than a reassurance.
• Buy only through a licensed hospital pharmacy or authorized distributor; a lack of a public alert is not a substitute for buying through a controlled chain of custody.
• See our full checklist in the guide to verifying a medicine is genuine.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Immune checkpoint inhibitors

Related high-cost medicines